Shanghai Fosun Pharmaceutical (Group) Beheer

Beheer criteriumcontroles 3/4

De CEO Shanghai Fosun Pharmaceutical (Group) is Deyong Wen, benoemd in Jan2022, heeft een ambtstermijn van 2.83 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 10.00M, bestaande uit 25.9% salaris en 74.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.004% van de aandelen van het bedrijf, ter waarde $ 350.12K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 3.4 jaar.

Belangrijke informatie

Deyong Wen

Algemeen directeur

CN¥10.0m

Totale compensatie

Percentage CEO-salaris	25.9%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.004%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Deyong Wen's beloning veranderd ten opzichte van Shanghai Fosun Pharmaceutical (Group)'s winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥10m	CN¥3m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥8m	CN¥2m	CN¥4b

Compensatie versus markt: De totale vergoeding ($USD 1.38M ) Deyong } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.78M ).

Compensatie versus inkomsten: De beloning van Deyong is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Deyong Wen (53 yo)

2.8yrs

Tenure

CN¥9,997,000

Compensatie

Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kexin Wang	Executive Co-Chairman	2.9yrs	CN¥15.25m	0.012% $ 1.1m
Yifang Wu	Executive Chairman	8.3yrs	CN¥12.14m	0.045% $ 4.1m
Deyong Wen	Joint President	2.8yrs	CN¥10.00m	0.0039% $ 350.1k
Xiaohui Guan	Executive Vice Chairman	2.9yrs	CN¥9.14m	0.011% $ 994.7k
Rongli Feng	Executive President & Chief Human Resources Office	less than a year	geen gegevens	0.0043% $ 383.3k
Jing Li	Executive President and CEO of Established Medicines Manufacturing & Supply Division	no data	geen gegevens	0.0043% $ 383.3k
Wang Xingli	Executive President	1.8yrs	geen gegevens	geen gegevens
Wenjie Zhang	Executive President & Co-CEO of Innovative Drug Division	1.8yrs	geen gegevens	geen gegevens
Zhanyu Chen	Senior VP & CFO	less than a year	geen gegevens	geen gegevens
Jia Yan	Director of the Accounting Department	no data	geen gegevens	geen gegevens
Dongjiu Li	Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee	3.7yrs	geen gegevens	0.0025% $ 225.3k
Donghua Wang	Senior VP & Chief Strategic Enabler	4.1yrs	geen gegevens	0.0043% $ 383.3k

2.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SFOS.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kexin Wang	Executive Co-Chairman	2.9yrs	CN¥15.25m	0.012% $ 1.1m
Yifang Wu	Executive Chairman	8.3yrs	CN¥12.14m	0.045% $ 4.1m
Deyong Wen	Joint President	2.3yrs	CN¥10.00m	0.0039% $ 350.1k
Xiaohui Guan	Executive Vice Chairman	2.9yrs	CN¥9.14m	0.011% $ 994.7k
Guliang Tang	Independent Non-Executive Director	5.4yrs	CN¥392.00k	geen gegevens
Qiyu Chen	Non-Executive Director	19.5yrs	geen gegevens	0.0043% $ 385.1k
Xiaoliang Xu	Non-Executive Director	5.4yrs	geen gegevens	geen gegevens
Ling Li	Independent Non-Executive Director	5.4yrs	CN¥392.00k	geen gegevens
Tze Shan Yu	Independent Non-Executive Director	3.4yrs	CN¥392.00k	geen gegevens
Yuqing Chen	Non-Executive Director	less than a year	geen gegevens	0.0058% $ 519.8k
Quandi Wang	Independent Non-Executive Director	3.4yrs	CN¥392.00k	geen gegevens
Bing Chen	Chief Supervisor	1.4yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SFOS.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Shanghai Fosun Pharmaceutical (Group) Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Recent updates

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces in Relation to the Approval for Drug Registration of Licensed Product

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022

Insilico Medicine Achieves Its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL

Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

Tianjin Kingyork Group Co., Ltd. signed the Equity Transfer agreement to acquire an additional 25.0011% stake in Tianjin Pharmaceutical Group Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) for CNY 1.4 billion.

Sisram Medical (Tianjin) Limited completed the acquisition of Shanghai Foshion Medical System Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Qianda (Tianjin) International Trading Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Receives from US FDA Regarding the Clinical Trial of FCN-159 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for 2020

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Update on the License Agreement Entered into by A Subsidiary

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Management Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2020 Results on Oct 29, 2020

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Elects Zhang Houlin as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Clinical Trial by A Subsidiary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) signed an agreement to acquire an additional 10% stake in YaoPharma Co., Ltd. for approximately CNY 740 million.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd